The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.
The opportunity that precision medicine presents in the field of oncology will be discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting, said David Debono, MD, medical director of oncology at Anthem.
AJMC®: What is the overall message you would like to convey to the audience at Patient-Centered Oncology Care® 2020?
Dr Debono: Oncology care in this era of precision medicine, we believe, is a huge opportunity for patients and their families. Anthem health plans are committed to its members, and we are also committed to the oncology community. And we will encourage high-value, precise care for all of its members with cancer.
AJMC®: What is Anthem’s approach to working with community oncology networks?
Dr Debono: We understand that 80% of oncology care is practiced in the community, and we value these oncologists. We understand that community oncologists have a commitment to their patients, to their patients' families, and to their communities. In that vein, we have developed a unique practice engagement model, where we have provider clinical liaisons centered in different regions of the company across the country.
These provider clinical liaisons, who are oncology nurses or oncology pharmacists, are collaborating with oncology practices across Anthem. These liaisons create a very productive relationship with practices where we can discuss our value-based strategies, where we can review our pathways program, and we can review other programs that we are developing within the oncology solutions team.
We are also providing palliative care resources. Palliative care resources are widely available at large institutions and academic centers. However, in the community, palliative care resources are somewhat scattered, if you will. So, we are providing palliative care resources which we believe complement the care that a busy oncologist is providing to its patient and family.
We've also expanded hospice care to allow for patients to receive oncology treatment while they are providing hospice care at the same time. This allows for patients and families not to make that excruciating decision to either continue the treatment that may be continuing to be beneficial or to move toward hospice care.
This hospice expansion allows for patients to continue their treatment and allows for the oncologist to have multiple conversations about high-quality end-of-life care as that patient progresses with their cancer journey.
We think that all these measures keep oncology care in the community and encourage high-quality, high-value care that we know is routinely practiced in the community.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More